Teladoc Strengthens Solo Platform With New AI-Powered Care Tools

Zacks
在Zacks上打开
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools

Teladoc Health, Inc. TDOC is expanding its Solo connected care platform with two new AI-powered tools designed to make virtual consultations more useful for clinicians and less cumbersome for hospitals. SoloVitals and SoloScribe address different bottlenecks in remote care: obtaining timely patient information and documenting visits without pulling attention away from patients.

SoloVitals uses the camera on a smartphone or tablet to estimate heart and respiratory rates by detecting subtle changes in facial skin color. The contactless approach could give clinicians another source of information during virtual assessments. SoloScribe, meanwhile, generates structured clinical notes and transfers summaries into electronic health records (EHR), potentially reducing repetitive documentation work.

By bringing these capabilities together within Solo, Teladoc is making its platform more useful for hospitals seeking to simplify their technology systems. Already installed in more than 15,000 care locations worldwide, Solo integrates with EHR systems such as Epic and Oracle Health. SoloScribe is now generally available, while SoloVitals is currently available to select customers through a private preview. Teladoc expects SoloVitals to reach full general release in December 2026.

The expansion could also strengthen Teladoc's position in the increasingly competitive virtual healthcare market. By combining clinical documentation and remote patient assessment within one platform, Teladoc could help hospitals reduce administrative workloads, improve clinical workflows and deliver more efficient patient care.

The introduction of these tools adds another dimension to Teladoc's efforts to strengthen its enterprise healthcare business. Growing demand for AI-enabled healthcare solutions provides an opportunity to expand its reach, while its established presence among hospitals and health systems offers a foundation for adoption. Wider adoption of these capabilities could strengthen customer retention, increase platform utilization and support sustainable revenue growth, contributing to Teladoc's long-term growth prospects.

TDOC’s Price Performance

Over the past six months, TDOC’s shares have gained 5.9% compared with the industry’s growth of 11.6%.

Zacks Investment Research
Image Source: Zacks Investment Research

TDOC’s Zacks Rank & Key Picks

TDOC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Medical space are Concentra Group Holdings Parent, Inc. CON, Phibro Animal Health Corporation PAHC and GeneDx Holdings Corp. WGS, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.

The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.

The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Teladoc Health, Inc. (TDOC): Free Stock Analysis Report
 
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
 
GeneDx Holdings Corp. (WGS): Free Stock Analysis Report
 
Concentra Group Holdings Parent, Inc. (CON): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research